Lineage Cell Therapeutics (LCTX) EBT (2016 - 2025)
Historic EBT for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.4 million.
- Lineage Cell Therapeutics' EBT fell 1396.2% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.0 million, marking a year-over-year decrease of 5974.76%. This contributed to the annual value of -$18.6 million for FY2024, which is 2018.73% up from last year.
- According to the latest figures from Q3 2025, Lineage Cell Therapeutics' EBT is -$3.4 million, which was down 1396.2% from -$19.3 million recorded in Q2 2025.
- Lineage Cell Therapeutics' EBT's 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$28.0 million in Q4 2021.
- Its 5-year average for EBT is -$7.4 million, with a median of -$6.0 million in 2025.
- Data for Lineage Cell Therapeutics' EBT shows a peak YoY increase of 8281.92% (in 2021) and a maximum YoY decrease of 294644.31% (in 2021) over the last 5 years.
- Quarter analysis of 5 years shows Lineage Cell Therapeutics' EBT stood at -$28.0 million in 2021, then skyrocketed by 77.29% to -$6.4 million in 2022, then increased by 25.9% to -$4.7 million in 2023, then surged by 31.06% to -$3.2 million in 2024, then fell by 5.23% to -$3.4 million in 2025.
- Its EBT stands at -$3.4 million for Q3 2025, versus -$19.3 million for Q2 2025 and -$6.0 million for Q1 2025.